The Benefit of Non-invasive Ventilation in Motor Neuron Disease

Walsh, Laura; Murphy, Desmond M.

doi:10.2174/1874306402014010053

Cited by 8 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in keeping with multiple studies including the only randomised control trial on this topic by Bourke et al 2006 [7, 12-17, 21, 30] Furthermore, there was signi cantly longer survival in those who used NIV optimally compared with those who never used NIV. This survival advantage has been previously demonstrated in several studies [7,15,31,32]. Of additional interest, those who used NIV regardless of compliance and pattern of onset survived 2 months longer on average than those who optimally used NIV.…”

Section: Resultssupporting

confidence: 61%

Use of Non-invasive Ventilation in Motor Neuron Disease – A Retrospective Cohort Analysis

Walsh

Deasy

Gómez

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Motor neuron disease (MND) is a neurodegenerative disorder which leads to progressive muscle weakness including respiratory muscle function decline. The introduction of non-invasive ventilation (NIV) has been shown to improve quality of life, survival and slow the rate of pulmonary function decline. Better compliance with the machine (using it for greater than 4 hours per day) has been shown to have the greatest long-term benefit. Methods A retrospective chart analysis of patients who attended the MND clinic from 2014-2019 at a tertiary-referral, academic, teaching hospital was carried out to evaluate if NIV and greater compliance with NIV was associated with improved survival. Information regarding NIV use, compliance, pulmonary function tests (PFTs) and basic patient demographics was collected. In total 111 patients were included in the study. Results The mean age at diagnosis was 63.8 years and 61.3% were males. 66.7% of our patient cohort used NIV and of this 44.1% were compliant. There was a statistically significant longer survival in those who used NIV (P=0.002) and in those who used NIV optimally (P=0.02) when both groups were compared to those who did not use NIV. In the bulbar MND group those who were compliant with NIV survived longer than who those who did not use NIV (P=0.001). Patients with bulbar onset MND had worse SNIP and peak cough flow values at diagnosis.Conclusion We found a significantly longer survival with the use of NIV, the use of NIV optimally and with use of NIV in those with bulbar onset MND compared to those who did not use NIV.

show abstract

Section: Resultssupporting

confidence: 61%

Use of Non-invasive Ventilation in Motor Neuron Disease – A Retrospective Cohort Analysis

Walsh

Deasy

Gómez

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…This survival advantage has been previously demonstrated in several studies. 7 , 15 , 31 , 32 Of additional interest, those who used NIV regardless of compliance and pattern of onset survived 2 months longer on average than those who optimally used NIV. This may be as a consequence of having smaller patient numbers in the optimal use NIV group ( n = 41 vs n = 93) and that this group had a slightly higher proportion of bulbar onset MND patients (51% vs 40.4%).…”

Section: Discussionmentioning

confidence: 99%

Use of non-invasive ventilation in motor neuron disease – a retrospective cohort analysis

et al. 2021

View full text Add to dashboard Cite

Motor neuron disease (MND) is a neurodegenerative disorder which leads to progressive muscle weakness including respiratory muscle decline. The introduction of non-invasive ventilation (NIV) has been shown to improve quality of life, survival and slow the rate of pulmonary function decline. A retrospective chart analysis of patients who attended the MND clinic from 2014 to 2019 at a tertiary-referral, academic, teaching hospital was carried out to evaluate if NIV and greater compliance with NIV was associated with improved survival. 111 patients were included. The mean age at diagnosis was 63.8 years and 61.3% were males. 66.7% of our cohort used NIV and of this 66.7%, 44.1% were compliant. There was a significantly longer survival in those who used NIV ( p = 0.002) and in those who used NIV optimally ( p = 0.02) when both groups were compared to those who did not use NIV. In the bulbar MND group those who were compliant with NIV survived longer than who those who did not use NIV ( p = 0.001). We found a significantly longer survival with the use of NIV, the use of NIV optimally and with use of NIV in those with bulbar onset MND compared to those who did not use NIV.

show abstract

“…NIV has been shown to improve quality of life and survival in MND, 11,12 but timing of initiation and monitoring measures are still unclear. 13 NIV is not always tolerated, especially in patients with bulbar dysfunction. There may be issues with leakage and skin trophic changes, which may be ameliorated by changing the type of mask used.…”

Section: Respiratory Dysfunctionmentioning

confidence: 99%